GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company’s principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. Businesses The company operates in three main areas, such as Pharmaceuticals, Vaccines, and Consumer Healthcare Pharmaceuticals The company’s Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of common acute and chronic diseases. Its Pharmaceuticals portfolio is made up of established medicines. The company is targeting research at a portfolio of potential next-generation treatments for respiratory disease, beyond the approach with inhaled medicines. In 2015, the company launched Nucala (mepolizumab), GSK’s first injectable biologic for severe asthma. Multiple other potential medicines targeting the underlying causes of respiratory disease are also in development. The company has a presence in HIV. Its global HIV business is managed through ViiV Healthcare, a company majority, 78.3% owned by the company. The company sells various other pharmaceutical products, including Benlysta, for the treatment of lupus disease, and Tanzeum/Eperzan, for Type 2 diabetes. The company’s Established Products portfolio includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of its Emerging Markets business. The company has a significant HIV R&D pipeline and is exploring new therapies for patients that could potentially enable long-term HIV control through infrequent dosing. In 2015, the company began phase III studies investigating its closed triple inhaled corticosteroid (ICS)/ long-acting muscarinic antagonist (LAMA)/ long-acting beta2 agonist(LABA) combination treatment (COPD), dolutegravir in combination with Janssen’s rilpivirine (HIV infection), sirukumab (giant cell arteritis) and retosiban (pre-term labour). Major advances within the company’s Pharmaceutical R&D portfolio include potential molecules in the field of epigenetics and immuno-oncology for the treatment of cancer, the next generation of respiratory medicines beyond inhaled treatments and a portfolio of new antibodies for inflammatory diseases including rheumatoid arthritis, autoimmune diseases and osteoarthritis. The company is investigating potential new options for long-term control and prevention of HIV, opportunities designed to cure or induce long-term remission in both Hepatitis B and C and, in Rare Diseases, potential breakthrough cell and gene therapies. In 2016, ViiV Healthcare acquired Bristol-Myers Squibb’s late stage HIV R&D assets and portfolio of preclinical and discovery stage HIV research assets. Vaccines This business develops, produces, and distributes approximately 1.9 million vaccines every day to people across the world. The company has a portfolio of 39 paediatric, adolescent, adult and travel vaccines. The company develops and makes vaccines that protect against a range of diseases. The company makes available 39 paediatric, adolescent, adult and travel vaccines that protect against 21 different diseases, including hepatitis, influenza, pneumococcal disease, rotavirus and cervical cancer. The company’s Vaccine R&D work focuses on discovering and developing new prophylactic and therapeutic vaccines to help protect and treat people against serious diseases. It has 15 candidate vaccines in early, mid and late-stage development against a range of diseases. The company has two novel candidate vaccines in phase II clinical development against respiratory syncytial virus (RSV) a common cause of bronchiolitis and pneumonia in infants that can lead to hospitalisation and an enhanced risk of severe asthma: one a paediatric RSV vaccine that uses a genetically engineered recombinant chimpanzee adenovirus – the
glaxosmithkline plc-spon adr
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|AbbVie Inc||$62.71 USD||+0.81|
|Allergan plc||$235.94 USD||+3.58|
|Medtronic PLC||$81.69 USD||+0.51|
|Mondelez International Inc||$44.78 USD||+0.43|
|Novo Nordisk A/S||kr371.00 DKK||-1.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.